{"id":924829,"date":"2026-01-07T08:51:39","date_gmt":"2026-01-07T13:51:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/"},"modified":"2026-01-07T08:51:39","modified_gmt":"2026-01-07T13:51:39","slug":"palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/","title":{"rendered":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn\u2019s disease (FSCD)<\/i><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>Carlsbad, CA, Jan.  07, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Crohn\u2019s &amp; Colitis Foundation (the \u201cFoundation\u201d), through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company\u2019s lead gut-microbiota-activated PDE4 inhibitor, being advanced for fibrostenotic Crohn\u2019s disease (FSCD) and moderate to severe ulcerative colitis (UC).<\/p>\n<p align=\"justify\">\u201cWe are honored to receive this strategic equity investment from the Crohn\u2019s &amp; Colitis Foundation through its IBD Ventures program,\u201d said J.D. Finley, Chief Executive Officer of Palisade Bio. \u201cThis investment represents a strong endorsement of both the scientific rationale underlying PALI-2108 and our targeted, gut-restricted approach to PDE4 inhibition. The Foundation\u2019s support further validates the potential of PALI-2108 to address the significant unmet needs of patients living with UC and FSCD, and we look forward to continuing to advance this program toward the next stages of clinical development.\u201d<\/p>\n<p align=\"justify\">\u201cWe\u2019re excited to be funding and working with Palisade Bio to address major unmet needs in fibrostenotic Crohn\u2019s disease and ulcerative colitis, where patients still face progression to strictures and surgery and limited treatment options,\u201d said Andr\u00e9s Hurtado Lorenzo, PhD, Senior Vice President of Translational Research and IBD Ventures at the Crohn\u2019s &amp; Colitis Foundation. \u201cPALI-2108 may help meet this need by directly targeting inflammation and fibrosis in the colon and ileum with limited systemic effects. Through our IBD Ventures program, we invest in promising, differentiated therapies like PALI-2108 to improve patient outcomes and advance innovative approaches for IBD.\u201d<\/p>\n<p align=\"justify\">Palisade has completed a Phase 1a single-ascending dose, multiple-ascending dose, and food-effect study of PALI-2108, followed by a Phase 1b cohort study in UC, and is currently evaluating PALI-2108 in an ongoing Phase 1b cohort study in FSCD. Data from these studies are expected to support Phase 2 Investigational New Drug (IND) submissions to the U.S. Food and Drug Administration (FDA) in 2026.<\/p>\n<p align=\"justify\">\n        <b>About PALI-2108<\/b><br \/>\n        \n      <\/p>\n<p align=\"justify\">PALI-2108 is an orally administered, prodrug engineered for local delivery of phosphodiesterase-4 (PDE4) inhibition to the terminal ileum and colon. The prodrug molecule is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is cleaved by bacterial enzymes to release its active PDE4 inhibitor metabolite directly at the site of inflammation and fibrosis. This targeted and slow-release design prevents absorption through the upper gut, achieves sustained local exposure and a longer half-life that enables once-daily dosing, and is engineered to produce a blunted peak plasma concentration to improve the overall therapeutic index. Together, these properties are intended to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure and reducing class-related tolerability issues, such as nausea and headache, that have limited systemic PDE4 inhibitors.<\/p>\n<p align=\"justify\">\n        <b>About the Crohn\u2019s &amp; Colitis Foundation<\/b>\n      <\/p>\n<p align=\"justify\">The Crohn\u2019s &amp; Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn\u2019s disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation\u2019s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OqJRl1gaVH8KbdJWxZbGM7dTAkJ0bkHxC8JcFjNg2TOWf7NxJsaK6KstYoq6LY6qcu_3s8ZooVBblrM0RoBtqiQHIxPwdjYhoRxLr4e_Ut7GF_DWyxIt1kDUsPLRQn_wSxwiocrYDLy7Il88sZzHYQ==\" rel=\"nofollow\" target=\"_blank\">www.crohnscolitisfoundation.org<\/a>, call 888-694-8872, or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N9eKuTvg_fAgV9k5zrYX2UOjENJtWINTEb9brRlcVXxEtww9-O2GEUYnpt4NjQglyhBZjwwbu8SkjANr9zM3i0zMlcJ6Zr42csi55eaa5SUQ39LrIev0nN5_UaYNOC-GV6BmSEsDnqmY-s-PAEIDug==\" rel=\"nofollow\" target=\"_blank\">info@crohnscolitisfoundation.org<\/a>.<\/p>\n<p align=\"justify\">\n        <b>About Palisade Bio<\/b>\n      <\/p>\n<p align=\"justify\">Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company advancing a next generation of, once daily, oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, PALI-2108, is a locally-bioactivated PDE4 inhibitor prodrug being developed for moderate-to-severe Ulcerative Colitis (UC) and fibrostenotic Crohn\u2019s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with sustained localized activation, low systemic exposure, and controlled release within the GI tract.<\/p>\n<p align=\"justify\">Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is preparing to initiate studies in FSCD to further characterize PALI-2108\u2019s safety, pharmacology and therapeutic benefit across inflammatory bowel disease indications. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kMNp5nXo071WNBaY0sDDMH9YWF-eVR252Pa7im3_83Ui5kUJZBz1uu2lsglQOufTMfAQrtam7ectcB8c9Kq5dq66PucEYqAUWFPGj3iwgJE=\" rel=\"nofollow\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b><br \/>\n        \n      <\/p>\n<p align=\"justify\">Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company\u2019s current expectations. Forward looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company\u2019s forward looking statements include, among others, the timing of enrollment, commencement and completion of the Company\u2019s clinical trials; the Company\u2019s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company\u2019s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward looking statements. These forward looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the Company\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC<br \/>Jenene Thomas<br \/>908-824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CEAglXF3mZdDObLtkFRa2T7xo6j1Ae4MiIDhU0GWM-CbvEVCA74CBTYET8wb-HDA-rlbqTrgTlfEN0ax5m7eDw==\" rel=\"nofollow\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTViMGE5MDgtNmJiYS00MTI4LTk4MTQtZjJkZmZkNzhiM2QxLTUwMDEwOTEyMS0yMDI2LTAxLTA3LWVu\/tiny\/Palisade-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn\u2019s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Crohn\u2019s &amp; Colitis Foundation (the \u201cFoundation\u201d), through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company\u2019s lead gut-microbiota-activated PDE4 inhibitor, being advanced for fibrostenotic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924829","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn\u2019s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Crohn\u2019s &amp; Colitis Foundation (the \u201cFoundation\u201d), through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company\u2019s lead gut-microbiota-activated PDE4 inhibitor, being advanced for fibrostenotic &hellip; Continue reading &quot;Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T13:51:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108\",\"datePublished\":\"2026-01-07T13:51:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/\"},\"wordCount\":1194,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/\",\"name\":\"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\",\"datePublished\":\"2026-01-07T13:51:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk","og_description":"PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn\u2019s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Crohn\u2019s &amp; Colitis Foundation (the \u201cFoundation\u201d), through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company\u2019s lead gut-microbiota-activated PDE4 inhibitor, being advanced for fibrostenotic &hellip; Continue reading \"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T13:51:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108","datePublished":"2026-01-07T13:51:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/"},"wordCount":1194,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/","name":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==","datePublished":"2026-01-07T13:51:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE3NCM3MzQ4MTk0IzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-strategic-equity-investment-from-the-crohns-colitis-foundations-ibd-ventures-program-to-advance-pali-2108\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio Announces Strategic Equity Investment from the Crohn\u2019s &amp; Colitis Foundation\u2019s IBD Ventures Program to Advance PALI-2108"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924829"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}